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Case presentation
Case 1. A 32-yr-old woman was admitted to New
England Medical Center Hospital (NEMCH) for
renal transplantation from her 27-yr-old brother af-
ter 5 months of dialysis treatment.
Approximately 8 months earlier, renal biopsy re-
vealed an advanced proliferative crescentic scleros-
ing glomerulonephritis. Immunofluorescent studies
revealed segmental, often peripheral, granular dep-
osition of immunoglobulins (especially IgA and
1gM) and complement (C3). Prednisone therapy
was begun, but the patient developed progressive
renal failure. Prednisone was discontinued, and
chronic hemodialysis was initiated 3 months after
the biopsy.
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The following tissue-typing data were available
prior to transplantation:
ABO blood
group Lymphocyte antigens
A All, Bw35, Cw4/A10
(Aw25), Bw16
A All, Bw35, Cw4/A10
(Aw25), Bw16
Pretranspiant "cross-match" test was negative.
Ten days following transplantation, the serum
creatinine concentration was 1.3 mgIlOO ml, and the
patient was discharged on a regimen of prednisone
(60 mg/day) and azathioprine (100 mg/day).
One day following discharge, the patient noted
blood-tinged urine, mild graft site tenderness, and
decreased urine output. Two days later, fever de-
veloped and the patient was readmitted to the hos-
pital. The renal graft site was no longer tender, and
there was no obvious swelling. Results of urinalysis
revealed 20 white blood cells/high power field and
two to three coarse granular casts. The serUm
creatinine concentration was 3.1 mg/l00 ml. Serum
concentrations of calcium, phosphorus, uric acid,
transaminases, and total protein and albumin were
normal. An i.v. urogram showed a very faint neph-
rogram of the transplanted kidney at 18 mm with no
evidence of obstruction. Methylprednisolone was
administered in an i.v. dosage of 1 g daily, for 3
days; oral administration of prednisone and azathio-
prine was continued. One day following admission,
a renal scan revealed adequate perfusion with poor
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function. Renal scans repeated 1 and 2 weeks later
revealed neither perfusion nor function, despite ad-
ministration of a second i.v. course of methlpred-
nisolone therapy (1 g daily, for three days). Chronic
hemodialysis therapy was reinstituted, and oral ad-
ministration of prednisone and azathioprine was
discontinued.
Five weeks after transplantation, transplant ne-
phrectomy was performed. Histologic sections
were consistent with diffuse interstitial rejection
and vascular rejection. There was subtotal in-
farction with focal areas of both arterial and venous
thrombosis. Two days after transplant nephrectomy
(3 weeks after discontinuing administration of im-
munosuppressive agents), a mixed lymphocyte cul-
ture reaction between the patient and the kidney do-
nor revealed a stimulation index of 2.5 and a rela-
tive response of 6%—a "negative" test result.
Case 2. A 20-yr-old woman was admitted to
NEMCH for renal transplantation from her 19-yr-
old brother.
Approximately 2.5 years earlier, renal biopsy had
revealed light and immunofluorescent microscopic
findings consistent with membranoproliferative gb-
merulonephritis. Electron microscopy had dis-
closed subepithelial and intramembranous electron-
dense deposits with focal areas of basement-mem-
brane-splitting.
The following tissue-typing data were available
prior to transplantation:
Pretransplant "cross-match" test was negative: a
mixed lymphocyte culture reaction was "negative"
with a stimulation index of 1.98 and a relative re-
sponse of 29%.
Within 48 hr after transplantation, the serum
creatinine level fell to 1.0 mg/100 ml. An i.v. uro-
gram and renal scan showed excellent transplant
function with no evidence of vascular or urinary
tract obstruction. Two weeks later, the serum
creatinine concentration was 0.8 mg/lOO ml, and the
patient was discharged on a regimen of prednisone
(50 mg/day), azathioprine (150 mg/day), proprano-
lol, and hydralazine.
Two days following discharge, the patient noted
fever, chills, and diffuse myalgia, and she was read-
mitted. The initial serum creatinine concentration
was 1.0 mg/l0O ml, but rose rapidly to 5.0 mg/100
ml. Methyiprednisolone was administered in an i.v.
dosage of 1 g daily, for 4 days, but the serum creati-
nine concentration increased progressively, and the
patient became oliguric. Hemodialysis was initi-
ated; oral administration of azathioprine and pred-
nisone was continued. Multiple cultures of blood
and urine were sterile. Renal scans showed ade-
quate perfusion with poor function. Two weeks af-
ter admission, a second i.v. course of methyl-
prednisolone therapy was administered (1 g daily,
for 2 days). During the next 3 days, the serum
creatinine concentration stabilized and then fell
without further dialysis. Four weeks following ad-
mission, the patient was discharged. One month lat-
er, the serum concentration of creatinine was 0.9
mg/l0O ml.
Discussion
Introduction. Because of the high rate of success
when HLA-identical siblings are selected as donors
for kidney transplantation, relatively little attention
has been paid to the fact that not all such trans-
plantations are successful. These two cases illus-
trate that serious rejection episodes can occur in
well-matched patients, leading in some cases to loss
of a graft. The overall incidence of graft failure from
rejection in HLA-identical sibling transplant pa-
tients is around 15%, and two thirds of these repre-
sent early failures (10% overall) within the first 6
weeks after transplantation [1]. Those patients who
experience transplant rejection do not differ signifi-
cantly in clinical manifestations or in the pathologic
appearance of the rejecting kidney, when compared
to individuals grossly mismatched for the HLA anti-
gens.
Of course, one must be certain that other causes
of renal failure in the graft have been considered.
First, the usual work-up to rule out infection or ob-
struction must be performed. One very interesting
form of infection that may mimic rejection is related
to cytomegalovirus (CMV). In this syndrome, there
may be decreased renal function with proteinuria,
elevated hepatic enzymes, lymphocytosis, gran-
ulocytopenia, and fever. Documentation of a rise in
antibody titer to CMV is essential to confirm the
diagnosis in retrospect. Second, one should consid-
er whether recurrent or de novo glomerulonephritis
is affecting the transplant. This is an interesting top-
ic in itself, but it is not our purpose to review it
here, today. In the present cases, there is no evi-
dence that glomerulonephritis was responsible for
decline in graft function.
Our main concern today revolves around the
question, Why are HLA-identical sibling grafts re-
jected? Before answering this question, it is neces-
ABO blood
group Lymphocyte antigens
Recipient
Donor
A Al, A29, B17, B400 A1,A29,B17,B40
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sary to review the current status of the human ma-
jor histocompatibility complex (MHC).
Major histocompatibility complex. On the short
arm of chromosome 6, there is a region known as
HLA containing the genes for the strong trans-
plantation antigens in man (Fig. 1). The main evi-
dence for the strength of these antigens comes, in
fact, from the success rate of transplantation be-
tween HLA-identical siblings compared with the
lower success rate when antigens of this region are
mismatched [11. The two primary classes of anti-
gens are defined by their function and biochemical
structure. The old nomenclature identified Class I
antigens as SD, serologically defined antigens.
Class II antigens were identified as LD, lympho-
cyte-defined antigens. Because Class II antigens are
now serologically definable, a new nomenclature
has become necessary.
Chromosome 6
'25cM
—5-1OcM
Centromere PGM3 GLO C2 Bf D (Bf) B C A C6o...+ +-.---
+-<1 cM-<1 cM-.
Fig. 1. Short arm of the human chromosome 6. TheHLA region
contains genes for three Class I loci (A,B,C) and one Class II
locus (D), which is defined by the mixed lymphocyte culture re-
action (MLR). Class II serologically defined antigens exist on B
lymphocytes and monocytes, which are D-related (DR). Some of
the enzyme and complement polymorphisms are also shown. cM
= centimorgan map unit.
Class I antigens are the classical serologically de-
fined HLA antigens of the A, B, and C loci, and
they are expressed on the surfaces of virtually all
body cells. The molecular structure for these anti-
gens consists of a light-chain (/32-microglobulin; mol
wt, 12,000 daltons) and a heavy-chain (mol wt,
33,000 daltons) that contains the antigenic specifici-
ty. Growing evidence suggests that Class I antigens
function in normal immunobiology to focus the ef-
fector mechanism in dealing with cells that have
been infected with viruses and possibly cells that
have undergone neoplastic transformation as well.
Class II antigens promote proliferation in vitro in
the so-called mixed lymphocyte culture reaction
(MLR) (Fig. 2). Class II antigens are related to the
D locus and have a molecular structure consisting
of two polypeptide chains of similar size (mol wt,
23,000 and 30,000 daltons). Antigens of the D locus
in man are analogous to antigens of the I region in
the mouse. In the I region of the mouse, genes con-
trolling immune responses to certain antigens have
been demonstrated (Ir genes) [2]. The cell surface
structures, which are alloantigens, are called Ia. It
is now clear that the surface Ia structures, which
are limited in distribution to B lymphocytes and
monocytes, being absent from T lymphocytes and
platelets, play an important role in cell-to-cell inter-
actions during the induction of the immune re-
sponse.
Additional genes of immunologic interest in the
HLA region are the certain complement of the com-
ponents: C2, Bf of the alternative pathway, C4, and
possibly C6. The C3b receptor for activated C3 is
also coded for by genes somewhere in the HLA re-
gion (Fig. 1).
There are over 50 defined antigenic specificities
for the Class I-A, B, and C loci and over 10 specific-
ities for the Class II-D locus [3]. These antigens are
inherited by simple Mendelian codominance, and
the cluster of antigens obtained by genetic transmis-
sion from each parent is called a haplotype (Fig. 3).
Each individual has two antigens of the A locus,
two of the B locus, two of the C locus, and two of
the D locus. The number of permutations and com-
binations of these antigens is extremely high, and
Allograft response
HLA antigen Host lymphocyte
-
Response
Anti-A, B, C
cytotoxic T
lymphocytes
Primarily
proliferative
Mixed
lymphocyte
response
T-cell-dependent
alloantibody
response
©A, B, C,
Amplifies
gM and lgG
Anti-A, B, C, D
antibodies
Fig. 2. Schema of the relative roles of HLA-A,B,C,D antigens in
initiation of the alloimmune response and in the development of
effector cells and antibodies. Two main classes of T lympho-
cytes recognize antigens: T, which are the precursors to the
cytotoxic "killer" cells; and TH, which are the helper cells for
amplication of the cytotoxic response. T11 also provide help to B
lymphocytes for production ofafully mature IgG response. Note
that T generally recognize Class I antigens, while the T11 sig-
nal is provided principally by the D antigens, which have Class
II antigens closely associated with them.
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one can see how difficult it is to obtain a complete
match for all eight antigens between unrelated indi-
viduals. In families, however, 25% of siblings are
identical for the entire HLA region; in other words,
they have the same haplotypes from their parents.
By the same token, 25% are totally dissimilar for
HLA, and the other 50% are semi-identical, sharing
one haplotype and differing for the other haplotype.
In approximately 1% of offspring, disruption of the
alleles inherited with a given haplotype occurs be-
cause of recombination during meiosis in one of the
parents; in other words, an offspring receives por-
tions of both parental haplotypes as a result of
crossing over. In transplantation matching for ex-
ample, when two siblings are identical for HLA-
A,B,C but differ for HLA-D, they cannot be consid-
ered HLA identical because they are mismatched
for that portion of the MHC that is crossed over.
The frequency of recombination in normal families
is an indication of the relative distance, or map dis-
tance, in the chromosomal segment, and, as stated
earlier, HLA-A,B,C,D recombination occurs in ap-
proximately 1% of offspring.
In a study of the relative roles of the Class I and
Class II antigens in human skin-grafting, Van Rood
has demonstrated that when skin grafts are ex-
changed between unrelated people who have been
carefully typed for the antigens of the HLA region,
there is an important effect of the HLA-D locus [4].
For example, if individuals have the same Class I
antigens of the A,B,C loci but are mismatched for
the Class II antigens of the D locus, the survival of
the graft seems to be directly related to the degree
of responsiveness in the MLR. The reverse situa-
tion, a Class II match and a Class I mismatch, re-
sults in some prolongation of graft survival. In con-
trast, alter immunization of the Class I antigens of
the A,B,C loci assume major importance because
immunity to Class I antigens shortens graft survi-
val, whereas immunity to the Class II antigens of
the D locus is of less importance.
It is necessary to remember that there is one oth-
er major histocompatibility system, the ABO blood
group system, which is important because the A
and B substances have been shown to be present on
the endothelium of blood vessels. In the present dis-
cussion of antigen matching, we are assuming there
is compatibility for the ABO system as well because
this genetic system is routinely matched in tissue-
typing laboratories.
Rejection in HLA-identical sibling transplant pa-
tients. The early rejection rate of HLA-identical
kidney transplants, as stated earlier, seems to be
around 10% [1]. Brief review of four recently pub-
lished series may help to put this in perspective. In
a study of 26 HLA-identical sibling transplant pa-
tients, Cheigh et al reported six graft failures [5].
Two of the grafts underwent accelerated acute re-
jection; one was described pathologically as a
Shwartzman reaction, and the other was associated
with a staphylococcal sepsis. A third graft failed
through acute rejection within the first week of
transplantation, similar to our first case today. The
other three grafts were chronically rejected, failing
with typical obliterative endarteritis. Mixed lym-
phocyte culture reactions were done only for the
two patients with accelerated rejection, and both re-
sponses were negative. In a report by Seigler et al
on 45 genotypically identical transplant patients,
complete family studies, including MLR, had been
performed to establish without question the HLA
identity of the siblings in question [6]. Of the 45 pa-
tients, 23 experienced mild reversible rejection; on
average, the rejection episodes began 15 days after
transplantation, but all 23 patients subsequently had
normal long-term function. Four patients developed
acute cellular rejection about I month after trans-
plantation and showed satisfactory, but incomplete,
recovery. Another five patients with acute cellular
rejection returned to normal function. Strikingly,
five patients developed acute humoral rejection,
confirmed by biopsy; three of the five rejections
were irreversible, onset occurring within 5 to 10
days after transplantation. In the same series, six
HLA region, chromosome 6
0w3 B8 Cw3 Al a
Owl ' '1 Bw35 Cw4 A29 b
Haplotypes:
a = Al, Cw3, B8, Dw3
b = A29, Cw4, Bw35, Owl
ar Al, Cw3, B8, Dwl
br = A29, Cw4, Bw35, Dw3
Inheritance:
ab X cd
I I I
ac ad bc bd
Fig. 3. Inheritance of HLA haplotypes. Each chromosomal seg-
ment of linked genes is termed a haplotype, and each individual
inherits one haplotype from each parent. The A,B,C,D antigens
of haplotypes a and b are shown for a hypothetical individual in
chromosomal order on the diagram, and also shown below as
they would be written in text. If individual ab were to marry cd.
their offspring would be four types only, as far as HLA is con-
cerned. Occasionally, recombination occurs in the germ line of a
parent, resulting in an altered haplotype (recombination repre-
sented by broken lines). The frequency of recombinant children
is a measure of the map distance (1% recombination frequency =
1 cM).
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patients showed evidence of recurrent glomerulone-
phritis. The overall graft success rate at 2 years was
87%, which is similar to that seen by Cheigh et al [5]
and in other published series. In a report on 17
HLA-identical sibling transplant patients, Ether-
edge et a! observed that rejection episodes were
more common in five patients with weakly positive
MLR responses and that a relatively strong MLR
response in one patient was associated with loss of
the graft from rejection [7]. Braun and Straffon
noted graft loss due to chronic rejection in 4 of 35
HLA-identical sibling transplant patients; the MLR
was negative in all 4 patients [8]. In one patient with
acute rejection and loss of the graft, there was an
HLA-D mismatch although the HLA-A,B,C anti-
gens were identical, an example of a recombinant
haplotype. A similar case was reported by Seigler et
al in an individual with acute humoral rejection
whose MLR was positive with the donor [6]. In our
own experience, we are aware of three instances of
apparent HLA recombination in which a Class I-
identical, MLR (Class 11)-incompatible graft was re-
jected, but there were also two patients in whom
rejection did not occur. The frequency of HLA-re-
combinant transplant patients is still relatively low,
but it is clear that rejection does occur when the D
locus is mismatched, and the rate seems to be as
high as that with HLA-A,B,C,D mismatched pa-
tients.
In contrast to some of the cases noted above,
there are good serologic data to show HLA identity
in the patients under discussion here today. In the
first case, the MLR was not performed until after
rejection and transplant nephrectomy had occurred.
It might be expected that a previously negative
MLR may turn positive when HLA-identical rejec-
tion has occurred, but this has not been well-docu-
mented. The stimulation index of 2.5 and the rela-
tive response of 6% has to be considered negative.
If the MLR had been performed during the time of
acute rejection, we might have expected a false neg-
ative response, which has been reported in some
patients and demonstrated experimentally in dogs
[9]. At the time of rejection, cells that specifically
react against donor antigens are not present in the
circulation, but are sequestered either in lymphoid
tissue or perhaps in the graft. The second patient
showed a negative stimulation index of only 1.98,
but when calculated as a relative response, it was
29%. We believe the latter method to be more accu-
rate because it is not as influenced by aberrations in
the control background cultures. This result sug-
gests that some degree of incompatibility might
have been present, but the response is still within
the range that we would consider a "match" for the
HLA-D locus. The stimulation index is simply the
ratio of the counts/mm of tritium-thymidine incor-
poration in the experimental mixture [recipi-
ent + donor (mitomycin treated)] compared to the
spontaneous counts in recipient cells alone; hence,
RDm/R. A better approach is the relative response,
which compares the experimental result with a con-
trol stimulation that is designated to be maximal.
The control stimulus is provided by an unrelated
cell donor or a mixture of unrelated cell donors. The
background is subtracted from both mixtures;
hence, (RDm — RRm)I(RCm — RRm) = relative re-
sponse.
Mixed lymphocyte culture reaction. The MLR
is therefore one approach to assessing incompati-
bility, which may be significant in unexpected re-
jection. There are three categories of positive MLR
among siblings.
First, there is the clear-cut recombinant between
the HLA-B and D loci. In this instance, siblings are
serologically identical for HLA-A,B,C, but have
strong MLR interactions. As noted above, these
transplant patients appear to run an increased risk
relative to true HLA identicals.
Second, there may be additional loci for MLR
proliferation on chromosome 6, mapping near the
HLA-A locus. Recent data on sibling MLR's that
indicate HLA recombination are summarized in
Table 1 [10]. Eight examples of HLA-B,D recombi-
nation had positive MLRs, as expected. Of 14
HLA-A,B recombinant siblings who had matching
HLA-B,D antigens and mismatched A antigens, six
had positive MLRs. The precise location of this sec-
ond MLR gene is unknown, and the matter may be
complicated by the role of suppressor genes; for ex-
ample, the MLR may be against the HLA-A antigen
itself and is manifest because a suppressor gene for
this response has crossed over with the segment
containing the B locus. If the locus is outside of
HLA-A,B,C,D, siblings could be completely
Table 1. MLR reactivity in HLA-recombinant siblings matched
for A and B (recombinants between B and D), or matched for B
and D (recombinants between A and B)a
MLR Response
Negative Positive
Recombinant between B & D 0 8
Recombinant between A & B 8 6
a Adapted from Ref. 10.
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matched for the known antigens, but still have an
important incompatibility on chromosome 6, which
may or may not be reflected in a weakly positive
MLR. Examples of important histocompatibility
antigens that are coded for by genes outside of the
MHC are now known in experimental animals. A
non-H2 skin graft rejection locus is found in the
mouse. A similar locus in the rat has recently been
localized to the chromosome carrying the MHC,
but it is outside of the region bearing the known
Class I and Class II antigens [11]. This incom-
patibility is not reflected by significant stimula-
tion in MLR. Chromosomes are inherited intact ex-
cept when recombination has occurred, and this is
more frequent when there is a greater distance be-
tween the markers in question. If HLA-B and D are
1 centimorgan apart (1% recombination rate), and a
postulated new histocompatibility locus is 10 centi-
morgans away from HLA, then we might expect a
10% "unexplained" rejection rate.
Third, the presence of antigens from other
chromosomes that are capable of stimulating the re-
sponse may produce a weakly positive MLR. In the
mouse, there is such a region called the M locus. Its
role in transplantation appears to be relatively mi-
nor, and no clear example of such a non MHC locus
has been discerned in other species, including man.
Nevertheless, this now brings us to consideration
of so-called minor transplantation antigens. Pre-
immunization to multiple minor antigens can result
in a state resembling a major histocompatibility bar-
rier. Whether the barrier always consists of a sum
total of dozens of such antigens or perhaps a limited
number of functionally important antigens is yet to
be determined. We must not forget that we continue
to rely on immunosuppressive agents in HLA-iden-
tical recipients because responses to non-HLA anti-
genic differences could be significant in every case
if untreated.
New approaches in tissue-typing. Clearly, more
attention must be paid to detection and character-
ization of antigenic differences and to states of anti-
genic presensitization, which are important in pa-
tients who are apparently well-matched for the nar-
row chromosomal region comprising HLA-
A,B,C,D. What procedures appear to show prom-
ise? The MLR, as reviewed above, could be of
some help when the response is weakly positive,
but sufficient data are not yet available on the pre-
dictive value of MLR alone. The observation that
multiply transfused individuals can make a "killer"
cell, lymphocyte-mediated cytotoxicity (LMC), re-
sponse to 51Cr-labeled target cells from HLA-identi-
cal siblings is of some importance [121. When used
as a cross-match procedure, this test was the only
indication in one patient of a serious anuric cellular
rejection, which began about one week after trans-
plantation. HLA-A,B,C,D were matched, and vari-
ous antibody cross-match tests were negative. This
circumstance is not common, and in fact a positive
LMC cross match is not consistently predictive of
severe rejection in patients mismatched for HLA
haplotypes [13]. When a positive MLR has evolved
in vitro, "killer" cells can be found that can damage
donor cells. This assay is called cell-mediated lym-
pholysis (CML) and is generally correlated with the
known HLA-A,B,C (Class I) antigenic differences
present. Not all killing is predictable by selection of
target cells that have the proper antigens, however,
and it is therefore likely that the CML test can be
used to type for antigens that are important to "kill-
er" cells, some of which are not directed to classi-
cal HLA antigens. Another experimental approach
to finding "extra" antigens is to restimulate cells
that have already responded once in the MLR. In
theory, only cells that have the same HLA-D anti-
gens as the stimulators in the first culture will pro-
duce an accelerated secondary response. In fact,
unexplained "extras" are being observed with this
technique, which is called primed lymphocyte typ-
ing (PLT).
What serological approaches show promise? We
are presently involved in an expanding investigation
of a variety of antibody cross-match procedures
that offer varying sensitivity and specificity. The
main focus is on B cell and macrophage antigens,
which are analogous to mouse Ia antigens and
closely related if not identical to the Class II MLR-
stimulating antigens. A number of antisera have
been found that identify serologically the HLA-D
locus, and the term HLA-DR is now used for the
serologically defined D-related antigens. A number
of sera appear to recognize non-D antigens, how-
ever, and some of these are not mapped to the
MHC. Hence, it may be possible to discern antigens
that are important in transplantation by testing sera
from rejected HLA-identical grafts, not only grafts
from kidney recipients, but from bone marrow re-
cipients as well. It is also important to note that
macrophages have antigens that are shared with
endothelial cells [14]. Some sera from multiparous
women have antibodies that react with macro-
phages and not with B lymphocytes, but they also
react with endothelium. The genetics of this system
are not yet clear, but it is possible that some HLA-
identical rejections may involve responses to this
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antigenic system. Presensitization to donor endo-
thelium could occur from macrophages present in
blood transfusion, for example.
What might have been done to prevent the diffi-
culties illustrated by these cases? Presently, we still
lack effective therapy for rejection when steroids
and azathioprine fail. These cases did not suffer
"hyperacute" rejections: hence, it is unlikely that
cross-match procedures can be definitive in them-
selves. A concerted effort is needed to define the
important antigenic systems that are being missed.
These mismatches are at least as important as the
standard HLA-haplotype mismatches. Further-
more, means to detect the presence of immunologi-
cal memory ("presensitization") to these antigens
will also be needed.
Questions and Answers
DR. J. J. COHEN: You have estimated that the in-
cidence of early graft rejection is 10%, even when
the donor and recipient are HLA-identical siblings
and the mixed lymphocyte culture reaction (MLR)
is negative. Would skin-grafting be helpful in identi-
fying those at risk of early rejection, or would this
technique potentiate the problem by sensitizing the
recipient to minor antigens?
DR. C. B. CARPENTER: When I first started as a
research fellow, this was exactly how histocompat-
ibility testing was done. The skin grafts were done
in the "reverse" direction—recipient to donor—
since one didn't want to sensitize the recipient. Re-
verse skin grafts were done mainly in siblings who
appeared to be identical twins, just to be absolutely
sure. At that time, there was a meager awareness of
major histocompatibility antigens. We knew about
identical twins, but there was even some confusion
about whether fraternal twins were really different
from siblings that were born at different times. It is
necessary to be very careful in the determination of
end points in skin graft tests because a difference of
2 or 3 days can be important biologically. Reverse
skin-grafting might be a nice assay in siblings who
are already well-typed for HLA antigens. If recipi-
ent and donor are totally HLA identical, skin graft
survival will be 28 to 30 days instead of the 10 to 12
days in unrelated individuals. Thus, skin-grafting
could be used when donor and recipient are com-
patible for HLA and in the MLR, for if skin graft
rejection occurs at 10 to 12 days, this would indicate
that another major incompatibility does exist be-
tween donor and recipient. One would hope, how-
ever, that the inconvenience and possible hazards
of sensitizing a normal sibling could be avoided. I
should now like Dr. Marvin R. Garovoy to describe
some of our studies in HLA-identical transplant pa-
tients who experienced rejection.
DR. M. R. GAROVOY (Associate Director, Tissue
Typing Laboratory, Peter Bent Brigham Hospital):
In the past 1.5 years, we have performed seven
transplants in patients who were HLA identical and
negative in the MLR. Two recipients had rejection
episodes, one mild and one severe, in the first 2
weeks after transplantation. We are employing as-
says for antibody-dependent lymphocyte-mediated
cytotoxicity (ADCC) and complement-dependent
cytotoxicity (CDC), which can detect the presence
of very low levels of antibodies including pre-
sensitization with minor antigens. Both of these re-
cipients had positive CDC and ADCC reactions.
Therefore, including the patient with positive LMC
"killer" cell reactivity mentioned by Dr. Carpenter
earlier, we have had three instances of documented
presensitization to minor antigens in HLA-identical
recipients, and all three patients had early episodes
of rejection.
DR. J. J. COHEN: Could rejection have been an-
ticipated in the patients under discussion today if
the CDC and ADCC tests had been done before
transplantation?
DR. M. R. GAROVOY: Perhaps. The tests were
done before transplantation in one of our patients,
but we did not appreciate their significance. In the
other two patients, the tests were not done before
the actual transplantation. In any event, we would
not have taken action because we are still collecting
data on these tests. Sufficient additional data must
be obtained before deciding to implement major
changes in the transplant protocol.
DR. C. B. CARPENTER: Another approach to pre-
dicting which HLA-identical patients will have re-
jection may develop from studies of the macro-
phage endothelium system. If this antigen system
becomes well-defined, it may be possible to use the
system clinically. Obviously, tissue-typing will be-
come too unwieldy if every minor antigen must be
typed. Perhaps there will be only one or two impor-
tant antigens among the minor antigens that are out-
side of the HLA region. Finding out which minor
antigens are important and typing them could be the
final check on HLA-identical recipients. I would
much prefer that to skin-grafting.
DR. J. J. COHEN: In view of the apparent physio-
logical function of the Class II antigens, is there any
likelihood that we will be able to attack the rejection
phenomenon by blocking the expression of these
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antigens so that host cells might recognize them dif-
ferently?
DR. C. B. CARPENTER: Well, some of us think
that this is how the phenomenon of enhancement
works. In rat models of organ transplantation in
which passive transfer of immune antidonor serum
blocks rejection, antibodies against Class II antigens
seem to be effective, whereas antibodies against
Class I antigens are not. We are in the process of
working this out in other combinations of inbred
rats to see how general a rule this is.
DR. J. T. HARRINGTON: Are experimental trans-
plant models in which donor and recipient are iden-
tical for Class II antigens but nonidentical for Class
I antigens being used to determine the relative im-
portance of these loci?
DR. C. B. CARPENTER: Yes, we have one such
combination of rat under study now, and we find
that untreated rejection of kidneys progresses at the
usual rate. Susceptibility to rejection modification,
however, may turn out to be different.
DR. N. E. MADIAS (NEMCH): Is there any evi-
dence that a difference in sex between the donor
and recipient might make a difference in graft
survival?
DR. C. B. CARPENTER: The published data on hu-
mans, mentioned earlier, do not differentiate the
sexes of donor and recipient. In inbred mice, it is
interesting that male-to-female grafts show a very
slow indolent rejection. The antigen associated with
the Y chromosome is thus a minor transplantation
antigen. Data in humans about the relative roles of
the ABO system [15] and male-to-female or female-
to-male renal transplants [8] are still incomplete. In
any case, the antigen associated with the Y chromo-
some is a minor one and is not likely to be the ex-
planation for the 10% incidence of early rejection,
as demonstrated by the two patients under dis-
cussion, today.
DR. . E. MADIAS: What are your thoughts re-
garding transfusions in potential cadaveric trans-
plant recipients? Could this practice promote en-
hancement?
DR. C. B. CARPENTER: Yes, but it is not clear
what is meant by enhancement when it is actively
produced. Blood transfusion may be beneficial in
some patients and harmful in other patients. I agree
with the current position that it is bad to avoid
transfusion in a potential cadaveric transplant recip-
ient. The data are quite firm on this.
DR. N. E. MADIAS: Can lymphocytotoxins be
isolated from rejected kidney tissue?
DR. M. R. GAROVOY: It is possible, depending on
the techniques you use, to isolate antibodies to
HLA-A,B,C loci antigens, and HLA-DR locus anti-
gens [16]. When indirect immunofluorescent tech-
niques are performed, these antibodies stain vascu-
lar endothelium [17].
DR. J. J. COHEN: Do we know for certain whether
the antibodies reach the kidney through the circula-
tion or through local production by cells?
DR. M. R. GAROVOY: Plasma cells actively syn-
thesizing antibodies are present in some grafts;
thus, there is the possibility of some local antibody
production in the rejecting kidney [18].
DR. J. J. COHEN: Is there a rapid serological test
to assay Class II antigens, which could possibly be
used in cadaveric transplantation?
DR. C. B. CARPENTER: Yes, this typing is being
done on an experimental basis presently. It takes a
little longer than the standard HLA typing and spe-
cifically identifies the HLA-DR antigens. It is nec-
essary to obtain prospective data from many trans-
plantation cases in order to determine the signifi-
cance of this kind of matching.
RENAL FELLOW: Is there any work being done to
explain how a pregnant woman can maintain a graft
in the form of a fetus for nine months without rejec-
tion?
DR. C. B. CARPENTER: It is clear that maternal
sensitization occurs to fetal HLA antigens during
pregnancy. This is, in fact, our main source of
HLA-typing reagents. Cellular immunity to HLA
has been demonstrated by the sensitive migration
inhibitory factor (MIF) assay, and antibodies to
HLA, particularly to Class II antigens, can block the
MIF response. Since women who are habitual spon-
taneous aborters lack these blocking antibodies, a
form of antibody-induced graft enhancement may
be partially responsible for the success of the fetus
as an allograft [19]. There are other possibilities as
well, and this is a fertile field for investigation.
Reprint requests to Dr. C. B. Carpenter, Renal Division, Im-
munology Laboratory, Department ofMedicine, HarvardMedi-
cal School, Peter Bent Brigham Hospital, 721 Huntington Ave-
nue, Boston, Massachusetts 02115, U.S.A.
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